Solve Therapeutics is a clinical-stage biopharmaceutical company advancing a pipeline of next-generation ADCs and a novel diagnostic platform for solid tumors. With its proprietary CloakLink hydrophilic linker system and a focus on selectively expressed tumor antigens, Solve is engineering therapeutics designed to safely and effectively offer benefit to patients with life-threatening cancers. Its diagnostic approach offers the potential of precise, noninvasive patient selection. The company is based in San Diego, CA.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/17/25 | $120,000,000 |
Abingworth Alexandria Venture Investments Ally Bridge Group AyurMaya B Capital Balyasny Asset Management DC Global Ventures General Atlantic Merck Global Health Innovation Fund Surveyor Capital Symbiosis Yosemite  | undisclosed |
